Spelling suggestions: "subject:"benign prostatic hyperplasia"" "subject:"denign prostatic hyperplasia""
1 |
The alphaâ†1-andrenoceptor subtype mediating contraction of the lower urinary tractNoble, Amanda Jane January 1997 (has links)
No description available.
|
2 |
Identification and evaluation of specific marker proteins associated with human benign peostate [sic] hyperplasia /Xu, Kexin, January 2002 (has links)
Thesis (M. Phil.)--University of Hong Kong, 2002. / Includes bibliographical references (leaves 166-207).
|
3 |
The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)Chan, Hin-cheong. January 2004 (has links)
Thesis (M.Nurs.)--University of Hong Kong, 2004. / Also available in print.
|
4 |
MR imaging biomarkers for benign prostatic hyperplasia pharmacotherapyJia, Guang, January 2006 (has links)
Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 87-93).
|
5 |
The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)Chan, Hin-cheong., 陳顯昌. January 2004 (has links)
published_or_final_version / Nursing Studies / Master / Master of Nursing in Advanced Practice
|
6 |
Identification and evaluation of specific marker proteins associated with human benign peostate [sic] hyperplasiaXu, Kexin, 許克新 January 2002 (has links)
published_or_final_version / Anatomy / Master / Master of Philosophy
|
7 |
Metabolic effects of 5α-reductase inhibition in humansUpreti, Rita January 2013 (has links)
5α-reductases (5αRs) catalyse reduction of 4-pregnene steroids, most notably the androgen testosterone to its more potent metabolite dihydrotestosterone (DHT). Well-characterised isozymes of 5αR are designated 5αR1 and 5αR2. Inhibitors of 5αR, finasteride (a 5αR2 inhibitor) and dutasteride (a dual 5αR1 and 5αR2 inhibitor), are utilised in conditions where a reduction in androgen action is desired, including benign prostatic hyperplasia. Although 5αR2 is predominantly expressed in reproductive tissues, both isozymes, but particularly 5αR1, are expressed in metabolic tissues including liver and adipose and both metabolise glucocorticoids as well as androgens; therefore inhibition of 5αR may have consequences for metabolic health. This thesis addresses the hypotheses that 5αR1 inhibition with dutasteride decreases insulin sensitivity and causes dysregulation of the HPA axis in humans. Metabolism and the HPA axis were studied in men prior to and following 3 months of dutasteride (0.5 mg daily; n=16), finasteride (5 mg daily; n=16) or control (tamsulosin MR; 0.4 mg daily; n=14). Glucose disposal during hyperinsulinaemia was the primary endpoint, measured during a hyperinsulinaemic euglycaemic clamp, with d2-glucose and d5-glycerol tracers. Peripheral insulin sensitivity for both glucose uptake and NEFA suppression decreased with dutasteride versus both finasteride and control, while hepatic insulin sensitivity was preserved. Body fat increased with dutasteride, though was not accompanied by changes in metabolic or inflammatory gene transcript abundance in subcutaneous adipose biopsies, nor any differences in abdominal adipose depots on post-treatment MRI. Subtle dysregulation of the HPA axis was evident with both 5αR inhibitors, though to a greater degree with dutasteride and changes were largely compensated for. In support of this study, this thesis also describes the development, validation and application of two novel liquid chromatography tandem mass spectrometry assays; establishing compliance by measuring serum drug levels, and demonstrating effects of 5αR inhibitors on androgen metabolism and adrenal steroidogenesis by measurement of testosterone, DHT and androstenedione. In conclusion, 5αR1 inhibition with dutasteride, but not finasteride, induces peripheral insulin resistance and increases body fat. Findings presented may have important implications for patients prescribed dutasteride for benign prostatic hyperplasia.
|
8 |
Balanced score cardPao-Shan, Hong 28 July 2006 (has links)
In recent years, domestic medicine companies limited by total value pay system can be regarded as depressing business. While some of medicine companies have been gradually losing their advantages, they, in addition to moving the production base to other countries, hope to find the suitable management system which completely subvert the way of thinking and traditional management skills as well for the purpose of improving the performance and competitiveness of company.
Balanced Score Card (BSC) was proposed in 1990 by Kaplan & Norton. This set of management systems is to establish company's vision and mission. According to the survey, BSC has already been introduced by a lot of listed companies or non-listed companies to enhance the business performance. Therefore, we can know that BSC has deeply influenced the operation of Taiwan's companies of. BSC breaks through the traditional limitation to measure the performance in financial views , constructs four major aspects to inspect operation of companies in terms of financials, customers, business internal process and organization learning to grow, and gives consideration to balance between financial performance and non financial performance, balance between long-term goal and short-term goal, balance between internal and external of company, linkage between performance measurement and operation objective, improving management performance measurement system. Application of BSC would convert the organization vision into concrete goal, link the goal with cause-effect relationship, guide the behavior of staff and organization by the performance measurement and incentives, and combine personal goal with company goal. High ranking managers can not only easily communicate with staffs, but also trace back the effectiveness of company operation. However, It is still unable to find out whether the domestic medicine companies selling benign prostatic hyperplasia drugs could use BSC to improve its company performances or not.
So, this research selects domestic medicine companies selling benign prostatic hyperplasia drugs as research object and investigates the effect of four major aspects such as financials, customers, business internal process and organization learning to grow, and influences of BSC on company's performance. Also, through qusetionaires and surveys, it would help domestic medicine companies selling benign prostatic hyperplasia drugs to set up the effective BSC system to raise company performance. The result of study can be offered to domestic medicine companies selling benign prostatic hyperplasia drugs as reference in the future.
|
9 |
A COMPARISON OF TRANSURETHRAL RESECTION OF THE PROSTATE AND MEDICAL TREATMENT FOR THE PATIENT WITH MODERATE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIAMIYAKE, KOJI, HIBI, HATSUKI, YAMAMOTO, MASANORI 29 March 1996 (has links)
No description available.
|
10 |
Androgen-induced norepinephrine release in male accessory sex organ smooth muscle growth and differentiationKim, Julie M., January 1999 (has links)
Thesis (Ph. D.)--West Virginia University, 1999. / Title from document title page. Document formatted into pages; contains vi, 125 p. : ill. Vita. Includes abstract. Includes bibliographical references (p. 107-122).
|
Page generated in 0.1005 seconds